Vascular endothelial dysfunction in the wake of HIV and ART

FEBS J. 2019 Apr;286(7):1256-1270. doi: 10.1111/febs.14657. Epub 2018 Sep 28.

Abstract

Mounting evidence points to increased rates of cardiovascular disease (CVD) among people living with HIV/AIDS (PLWHA). Endothelial dysfunction (loss of endothelium-dependent vascular relaxation in response to provasodilatory stimuli) constitutes an early pathophysiological event in atherogenesis and CVD. Both HIV-1 infection and antiretroviral therapy (ART) are implicated in the development of endothelial dysfunction; however, conclusions are frequently drawn from associations shown in epidemiological studies. In this narrative review of mainly in vitro and animal studies, we report on the current understanding of how various HIV-1 proteins, HIV-1-induced proinflammatory cytokines and common antiretroviral drugs directly impact vascular endothelial cells. Proposed cellular mechanisms underlying the switch to a dysfunctional state are discussed, including oxidative stress, impaired expression and regulation of endothelial nitric oxide (NO) synthase (eNOS) and increased expression of vascular adhesion molecules. From the literature, it appears that increased reactive oxygen species (ROS) production, linked to decreased NO bioavailability and ensuing endothelial dysfunction, may be proposed as a putative final common pathway afflicting the vascular endothelium in PLWHA. The HIV-1-proteins Tat, Gp120 and Nef in particular, the proinflammatory cytokine, TNF-α, and the antiretroviral drugs Efavirenz and Lopinavir, most commonly postulated to be primary causal agents of endothelial dysfunction, are also discussed. We conclude that, despite existing evidence from basic research papers, a significant gap remains in terms of the exact underlying cellular mechanisms involved in HIV-1 and ART induced endothelial dysfunction. Bridging this gap could help pave the way for future strategies to prevent and treat early cardiovascular changes in PLWHA.

Keywords: HIV-induced proinflammatory cytokines; HIV-proteins; antiretroviral therapy; endothelial dysfunction; endothelial nitric oxide synthase; human immunodeficiency virus; nitric oxide; oxidative stress; reactive oxygen species; vascular endothelium.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Retroviral Agents / adverse effects*
  • Cardiovascular Diseases / chemically induced
  • Cardiovascular Diseases / pathology*
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / pathology*
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • HIV Infections / virology
  • HIV-1 / drug effects*
  • Humans
  • Nitric Oxide / metabolism*
  • Oxidative Stress / drug effects*

Substances

  • Anti-Retroviral Agents
  • Nitric Oxide